PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche

Journal of Translational Medicine

Christina AM Jamieson³  Anna A Kulidjian⁵  Nicholas A Cacalano²  Omer Raheem⁴  Takeshi Hirata¹  Michael A Liss⁴  Wenxue Ma³  Jason R Woo⁴  Seung Chol Park⁶  Christina N Wu³  Amy Strasner³  Michelle Muldong³  Elana Godebu⁴ 

[1] Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan;Department of Radiation Oncology, University of California, Los Angeles, CA, USA;Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA;Department of Surgery, University of California, San Diego, La Jolla, CA, USA;Division of Orthopedic Surgery, University of California, San Diego (UCSD), La Jolla, CA, USA;Department of Urology, Wonkwang University School of Medicine and Hospital, Iksan, South Korea

关键词: Tumor microenvironment;    Androgen deprivation therapy;    Castrate-resistant;    Bone metastatic prostate cancer;    Xenograft;   

Others  :  1147831
DOI  :  10.1186/s12967-014-0275-1

 received in 2014-08-13, accepted in 2014-09-22,  发布年份 2014

【 摘 要 】

Introduction

Prostate cancer bone metastasis occurs in 50-90% of men with advanced disease for which there is no cure. Bone metastasis leads to debilitating fractures and severe bone pain. It is associated with therapy resistance and rapid decline. Androgen deprivation therapy (ADT) is standard of care for advanced prostate cancer, however, bone metastatic prostate cancer (PCa) often becomes resistant to ADT. There are few pre-clinical models to understand the interaction between the bone microenvironment and prostate cancer. Here we report the castrate resistant growth in the bone niche of PCSD1, a patient-derived intra-femoral xenograft model of prostate bone metastatic cancer treated with the anti-androgen, bicalutamide.

Methods

PCSD1 bone-niche model was derived from a human prostate cancer femoral metastasis resected during hemiarthroplasty and serially transplanted into Rag2^?/?;?_c^?/? mice intra-femorally (IF) or sub-cutaneously (SC). At 5 weeks post-transplantation mice received bicalutamide or vehicle control for 18 days. Tumor growth of PCSD1 was measured with calipers. PSA expression in PCSD1 xenograft tumors was determined using quantitative RT-PCR and immunohistochemistry. Expression of AR and PSMA, were also determined with qPCR.

Results

PCSD1 xenograft tumor growth capacity was 24 fold greater in the bone (intra-femoral, IF) than in the soft tissue (sub-cutaneous, SC) microenvironment. Treatment with the anti-androgen, bicalutamide, inhibited tumor growth in the sub-cutaneous transplantation site. However, bicalutamide was ineffective in suppressing PCSD1 tumor growth in the bone-niche. Nevertheless, bicalutamide treatment of intra-femoral tumors significantly reduced PSA expression (p?

Conclusions

PCSD1 tumors were castrate resistant when growing in the bone-niche compared to soft tissue. Bicalutamide had little effect on reducing tumor burden in the bone yet still decreased tumor PSA expression and increased AR expression, thus, this model closely recapitulated castrate-resistant, human prostate cancer bone metastatic disease. PCSD1 is a new primary prostate cancer bone metastasis-derived xenograft model to study bone metastatic disease and for pre-clinical drug development of novel therapies for inhibiting therapy resistant prostate cancer growth in the bone-niche.

【 授权许可】

   
2014 Godebu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics. CA Cancer J Clin 2014, 64:9-29.
• [2]Desireddi NV, Roehl KA, Loeb S, Yu X, Griffin CR, Kundu SK, Han M, Catalona WJ: Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007, 70:950-955.
• [3]Sturge J, Caley MP, Waxman J: Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol 2011, 8:357-368.
• [4]Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, et al.: Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014, 12:686-718.
• [5]Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
• [6]Swanson GP: Primary hormone therapy for locally advanced prostate cancer. Curr Urol Rep 2006, 7:225-232.
• [7]Kim HS, Freedland SJ: Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care 2010, 4:147-152.
• [8]de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, et al.: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
• [9]Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, De Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, De Bono JS: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
• [10]Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C: Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013, 14:1193-1199.
• [11]Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV: Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014, 65:30-36.
• [12]Culig Z: Targeting the androgen receptor in prostate cancer. Expert Opin Pharmacother 2014, 15:1427-1437.
• [13]Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ: Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011, 17:4854-4861.
• [14]Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA: A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med 2011, 9:185-5876-9-185.
• [15]Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, Wei J, Zhai D, Geron I, Pu M, Bao L, Chuang R, Balaian L, Gotlib J, Minden M, Martinelli G, Rusert J, Dao KH, Shazand K, Wentworth P, Smith KM, Jamieson CA, Morris SR, Messer K, Goldstein LS, Hudson TJ, et al.: A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 2013, 12(3):316-328. Epub 2013 Jan
• [16]Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH: NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PLoS One 2012, 7(6):e39725. Epub 2012 Jun 29
• [17]Hsu WK, Virk MS, Feeley BT, Stout DB, Chatziioannou AF, Lieberman JR: Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT. J Nucl Med 2008, 49(3):414-421. Epub 2008 Feb 20
• [18]Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane CJ, Karin M, Jamieson CA: Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med 2014, 12:30. BioMed Central Full Text
• [19]Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL: Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011, 19(5):575-586. doi:10.1016/j.ccr.2011.04.008
• [20]Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK: Inhibition of androgen receptor and ?-catenin activity in prostate cancer. Proc Natl Acad Sci U S A 2013, 110(39):15710-15715.
• [21]Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK: Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene 2013, 32(34):3992-4000. Epub 2012 Sep 17
• [22]Schmidt LJ, Duncan K, Yadav N, Regan KM, Verone AR, Lohse CM, Pop EA, Attwood K, Wilding G, Mohler JL, Sebo TJ, Tindall DJ, Heemers HV: RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol 2012, 26(5):716-735. Epub 2012 Mar 28
• [23]Jamieson CAM, Yamamoto KR: Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. Proc Natl Acad Sci U S A 2000, 97(13):7319-7324.